The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Risk and health care costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
D. Weycker
Research Funding - Amgen
J. Edelsberg
Research Funding - Amgen
A. Kartashov
Research Funding - Amgen
R. Barron
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
G. H. Lyman
Consultant or Advisory Role - Amgen
Research Funding - Amgen